Newly renamed Novo Nordisk is facing fierce competition in the weight-loss drugs sector it pioneered (Michal Cizek) Danish pharmaceuticals giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Monday a name change to just Novo, hoping it will be more "memorable and relevant" for clients. The rebrand comes ahead of a strategic presentation on September 21, when executives are to lay out their plan for "a faster, more competitive and increasingly consumer-driven market". The company is battling fierce competition in the anti-obesity sector, where its hugely successful Ozempic and Wegovy treatments have spurred rivals to catch up.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.